Technology | June 22, 2015

ScanMed Introduces Non-Invasive Procure Prostate/Pelvic MRI Coil for Diagnosing Prostate Cancer

Device offers higher image quality, reducing high rates of false positives

ScanMed, ProCure, prostate/pelvic MRI coil, prostate cancer

June 22, 2015 - ScanMed announced the introduction of the non-invasive, wearable ProCure prostate/pelvic magnetic resonance imaging (MRI) coil to aid in diagnosing prostate cancer

According to the National Cancer Institute, prostate cancer is the most common cancer (1 of 6 men) inflicting men in the United States, after skin cancer. It is the second leading cause of death from cancer in men.

Men with elevated prostate-specific antigen (PSA) will often get a blind biopsy and are given a clean ill of health, even though such biopsies are reported to yield between 50 and 90 percent false negatives, meaning that the man did have cancer and it went undetected. After a cancer is left to grow for too long, then options are very few in terms of treatment - either complete removal of the prostate (prostatectomy) or thermal ablation of the entire organ.

The ProCure coil was born from evaluation of the current MRI tools available - non-dedicated antennae and endo-rectal coils that produced inadequate image quality or great reluctance or refusal of use, respectively. ProCure is a dedicated, diaper-like MRI coil which positions multiple antennae elements as close as possible to the target anatomies (the prostate and reproductive organs) regardless of patient size. The coil also allows for biopsy should a radiologist deem that a detected lesion warrants laboratory validation.

For more information: www.scanmed.com

Related Content

Toshiba Showcases MRI Workflow Enhancements at RSNA 2017
News | Magnetic Resonance Imaging (MRI) | September 21, 2017
September 21, 2017 — Toshiba Medical will highlight its latest...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Siemens Healthineers to Showcase Magentom Vida MRI at RSNA 2017
Technology | Magnetic Resonance Imaging (MRI) | September 18, 2017
September 18, 2017 — Siemens Healthineers announced it will display the new Magnetom Vida 3T...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents
News | Contrast Media | September 12, 2017
The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC) voted overwhelmingly...
News | Imaging | September 11, 2017
September 11, 2017 — Innovatus Imaging Corp., a newly created holding company formed by private equity firm Resilienc
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Sponsored Content | Videos | Radiation Therapy | September 08, 2017
The new Visicoil MR is a helically-wound, flexible linear fiducial marker.
CIRS Launches New MRI Distortion Check Software
Technology | Magnetic Resonance Imaging (MRI) | September 06, 2017
MRI Distortion Check is a new, cloud-based solution designed to quickly and automatically quantify distortion in...
Overlay Init